Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jemincare Out-Licenses Global Rights (ex-China) for Novel Pain Drug to Finland’s Orion

publication date: May 6, 2022

Shanghai Jemincare Pharmaceuticals out-licensed global rights (ex-China) for a novel pain medication to Orion Corporation, a Finnish pharmaceutical company. Jemincare was recently approved to start a China Phase I trial of the selective NaV 1.8 blocker for acute and chronic pain. NaV 1.8 is a sodium channel subtype that modulates the excitability of pain fibers. Although NaV 1.8 has been shown to play a pivotal role in pain transmission, there are no approved drugs for the target currently. Orion will make a $16 million upfront payment for the rights, plus unspecified milestones and 8%-15% royalties on sales. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital